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Multiple Sclerosis (MS) is a representative autoimmune
demyelinating disease of the central nervous system
(CNS) affecting mainly young adults. Clinician's interests
are mainly focused on the physical impairment that MS
may bring. However, during the past few decades there is
an increasing awareness of cognitive dysfunction in MS
patients, a symptom already described for MS cases by
Charcot. It is estimated that cognitive dysfunction may be
present in more than 50% of the MS patients during their
lifetime and may cause a devastating impact on every day
function, independently on the degree of physical disabil-
ity. In several neuropsychological studies it has been
reported that recent memory, attention, processing speed,
visuospatial abilities and executive functions, are among
the domains of cognitive function most commonly
affected in MS. On the contrary, language skills and intel-
lectual functions are generally preserved. However,
patients may either underestimate their deficits due to
metamemory impairment or overestimate them due to
depression. In addition, one of the major problems in the
every day clinical practice remains the assessment of cog-
nitive function, since the mini – mental state examination
which is included in a routine neurological evaluation, is
insensitive to MS-related cognitive impairment, especially
a non-severe one. It is therefore evident that a brief, cost-
effective and reliable neuropsychological assessment may
be of a great value and may contribute to a global evalua-
tion of the disease progression in an individual patient.
During the last decade, an enormous progress in MS treat-
ment has been made. However, most clinical trials of dis-
ease modifying therapies have been focused on the role of
the administered agents in controlling the physical disa-
bility of MS patients. Only in a few multicenter studies
cognitive function was among the outcomes studied and
preliminary results indicate that currently used immu-
nomodulatory and symptomatic agents may positively
influence the cognitive outcome of the patient. There is
considerable hope that by altering the cerebral demyeli-
nating process, a slower decline in cognitive functions
may be accomplished. Furthermore, combination of drug
therapy with cognitive rehabilitation techniques is
expected to result in the improvement of the quality of life
standards of the MS patients.
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